AU2021372454A1 - Treatment of cancers with gm-csf antagonists - Google Patents

Treatment of cancers with gm-csf antagonists Download PDF

Info

Publication number
AU2021372454A1
AU2021372454A1 AU2021372454A AU2021372454A AU2021372454A1 AU 2021372454 A1 AU2021372454 A1 AU 2021372454A1 AU 2021372454 A AU2021372454 A AU 2021372454A AU 2021372454 A AU2021372454 A AU 2021372454A AU 2021372454 A1 AU2021372454 A1 AU 2021372454A1
Authority
AU
Australia
Prior art keywords
antibody
cancer
csf
patient
csf antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021372454A
Other languages
English (en)
Other versions
AU2021372454A9 (en
Inventor
Luis Carvajal
Annalisa D'ANDREA
Joe PIRRELLO
Eben TESSARI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kiniksa Pharmaceuticals GmbH
Original Assignee
Kiniksa Pharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kiniksa Pharmaceuticals GmbH filed Critical Kiniksa Pharmaceuticals GmbH
Publication of AU2021372454A1 publication Critical patent/AU2021372454A1/en
Publication of AU2021372454A9 publication Critical patent/AU2021372454A9/en
Assigned to KINIKSA PHARMACEUTICALS, GMBH reassignment KINIKSA PHARMACEUTICALS, GMBH Request for Assignment Assignors: KINIKSA PHARMACEUTICALS, LTD.
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU2021372454A 2020-10-26 2021-10-26 Treatment of cancers with gm-csf antagonists Abandoned AU2021372454A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063105773P 2020-10-26 2020-10-26
US63/105,773 2020-10-26
US202063120319P 2020-12-02 2020-12-02
US63/120,319 2020-12-02
US202163242849P 2021-09-10 2021-09-10
US63/242,849 2021-09-10
PCT/US2021/056700 WO2022093855A1 (en) 2020-10-26 2021-10-26 Treatment of cancers with gm-csf antagonists

Publications (2)

Publication Number Publication Date
AU2021372454A1 true AU2021372454A1 (en) 2023-06-22
AU2021372454A9 AU2021372454A9 (en) 2024-09-12

Family

ID=78820846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021372454A Abandoned AU2021372454A1 (en) 2020-10-26 2021-10-26 Treatment of cancers with gm-csf antagonists

Country Status (6)

Country Link
US (1) US20220184179A1 (https=)
EP (1) EP4232162A1 (https=)
JP (1) JP2023546657A (https=)
KR (1) KR20230095983A (https=)
AU (1) AU2021372454A1 (https=)
WO (1) WO2022093855A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240309079A1 (en) * 2023-03-14 2024-09-19 Taran Therapeutics, Inc. Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations
WO2025096692A2 (en) * 2023-11-01 2025-05-08 Taran Therapeutics, Inc. Combination treatment of chronic myelomonocytic leukemia in patients with ras pathway mutations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
RU2447085C2 (ru) 2005-05-18 2012-04-10 МорфоСис АГ Анти-gm-csf антитела и их применение
JP4943044B2 (ja) 2005-07-20 2012-05-30 リンテック株式会社 粘着シート
MX2008012291A (es) 2006-03-27 2009-01-12 Medimmune Ltd Miembro que enlaza al receptor gm-csf.
CN103827143A (zh) * 2011-07-06 2014-05-28 莫弗系统股份公司 抗cd20抗体和抗gm-csf抗体的治疗性组合产品及其用途
WO2013026059A1 (en) * 2011-08-18 2013-02-21 New York University Inhibition of oncogenic kras-induced gm-csf production and function
CA2851322C (en) 2011-10-10 2020-03-31 Medimmune Limited Treatment for rheumatoid arthritis with gm csfr alpha antibodies
CN106456761A (zh) 2014-05-19 2017-02-22 免疫医疗有限公司 对类风湿关节炎的治疗
EP3786293A1 (en) 2015-06-12 2021-03-03 AxioMx, Inc. Methods and compositions for producing a chimeric polypeptide
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
AU2018345751A1 (en) * 2017-10-02 2020-05-07 Humanigen, Inc. Methods of treating immunotherapy-related toxicity using a GM-CSF antagonist
CN109120869B (zh) * 2018-11-07 2024-09-06 深圳市道通智能航空技术股份有限公司 双光图像整合方法、整合设备及无人机
AU2019377515A1 (en) * 2018-11-09 2021-05-27 Kiniksa Pharmaceuticals, Gmbh Treatment for giant cell arteritis
US20220331425A1 (en) * 2019-06-03 2022-10-20 Kiniksa Pharmaceuticals, Ltd. Treatment of cancers with gm-csf antagonists

Also Published As

Publication number Publication date
KR20230095983A (ko) 2023-06-29
WO2022093855A1 (en) 2022-05-05
US20220184179A1 (en) 2022-06-16
AU2021372454A9 (en) 2024-09-12
JP2023546657A (ja) 2023-11-07
EP4232162A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
ES2858091T3 (es) Moléculas de unión que se unen a PD-L1 y LAG-3
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
US20220331425A1 (en) Treatment of cancers with gm-csf antagonists
CN106413751A (zh) 用于治疗癌症的抗ccr4抗体和4‑1bb激动剂的组合
CN116249548A (zh) 用于治疗多发性骨髓瘤的方法
US20230340122A1 (en) Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
JP2022512642A (ja) がんを治療するための抗ＭｅｒＴＫ抗体
WO2023041622A1 (en) Selection of responders for anti-btn3a treatment
JP2024167261A (ja) 抗原結合タンパク質
US20220184179A1 (en) Treatment of cancers with gm-csf antagonists
CN114630839B (zh) 抗ox40抗体及其用途
TW202028226A (zh) Ｉｌ－１５蛋白複合物聯合ｐｄ－ｌ１抗體用於治療腫瘤疾病的用途
CN116685352A (zh) 用gm-csf拮抗剂治疗癌症
CN115551553A (zh) 治疗皮肤t细胞淋巴瘤和tfh起源淋巴瘤的新方法
US20250195653A1 (en) Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
WO2024175699A1 (en) Combination of btn3a activating antibody and immune checkpoint inhibitors
HK40057934A (en) Binding molecules binding pd-l1 and lag-3
HK1233518A1 (en) Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: KINIKSA PHARMACEUTICALS, GMBH

Free format text: FORMER APPLICANT(S): KINIKSA PHARMACEUTICALS, LTD.

SREP Specification republished
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period